With eczema reaching epidemic levels worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is an increasing need for safer and more effective treatments. According to DelveInsight, the eczema pipeline includes over 100 pharmaceutical and biotech companies developing more than 100 therapeutic candidates. These therapies are in various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this major public health challenge.
DelveInsight’s “Eczema Pipeline Insight 2025” report provides a comprehensive and strategic assessment of the R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive dynamics, and key company initiatives. The report is an essential resource for stakeholders—including researchers, healthcare investors, and decision-makers—seeking insights into the evolving eczema therapeutics market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Eczema Drug Development @ https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Eczema Pipeline Report
-
DelveInsight’s eczema pipeline report highlights a dynamic landscape, featuring over 100 active companies developing more than 100 therapeutic candidates for eczema treatment.
-
Significant advancements have occurred in recent years. On April 18, 2025, the U.S. FDA approved Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older who remain symptomatic despite antihistamine therapy. This marks Dupixent as the first targeted therapy for CSU in over a decade, offering a new option for patients with this chronic condition.
-
Earlier, in September 2024, the FDA approved Ebglyss™ (lebrikizumab), a monoclonal antibody targeting interleukin-13, for moderate-to-severe atopic dermatitis in patients aged 12 and older, providing an alternative for individuals not responding adequately to existing therapies.
-
Key companies advancing the eczema treatment landscape include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
-
Notable pipeline candidates under development include Amlitelimab, BX-005, LP-0145, and several other promising therapies at various stages of clinical investigation.
Eczema Overview:
Eczema, also known as atopic dermatitis, is a prevalent skin disorder characterized by dry, itchy skin that can become inflamed or infected. While it often begins in childhood, adults can also be affected. The condition is influenced by both genetic and environmental factors and is sometimes referred to as “the itch that rashes”, since scratching can exacerbate symptoms. Typical signs include red, dry patches—commonly on the cheeks, elbows, knees, hands, or feet—that may crack, blister, or bleed.
Maintaining skin hydration is crucial for managing eczema, with topical steroids used during flare-ups. The condition affects roughly 15–30% of children and 2–10% of adults, with most cases appearing within the first year of life. Symptoms can interfere with sleep and daily activities. Management often involves allergists, especially when allergies are triggers, and may include moisturizers, ointments, antihistamines, and avoiding irritants such as wool, harsh soaps, or allergens like dust, pets, and pollen.
Download the Eczema sample report to know in detail about the Eczema treatment market
Eczema Pipeline Analysis
The Eczema pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Eczema Market.
-
Categorizes Eczema therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Eczema drugs under development based on:
-
Stage of development
-
Eczema Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Eczema Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Eczema Licensing agreements
-
Funding and investment activities supporting future Eczema market advancement.
-
Unlock key insights into emerging Eczema therapies and market strategies here: https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Eczema Emerging Drugs
-
Amlitelimab: Kymab
Amlitelimab (SAR445229, formerly KY1005) is a human monoclonal antibody that targets OX40L, aiming to restore immune balance by reducing pro-inflammatory T cells while enhancing anti-inflammatory regulatory T cells, without broadly suppressing immunity. In Phase I trials, it successfully inhibited T cell–mediated skin inflammation and was well tolerated. Its immune-modulating properties suggest potential for treating multiple autoimmune conditions. Amlitelimab is currently in Phase II trials for eczema.
-
BX 005: BiomX
BX005 is a topical phage cocktail developed to target Staphylococcus aureus (S. aureus), a bacterium associated with atopic dermatitis. In preclinical in vitro studies, BX005 was effective against over 90% of S. aureus strains collected from skin samples in the U.S. and Europe, including antibiotic-resistant strains. The therapy is currently being evaluated in Phase I/II clinical trials for the treatment of atopic dermatitis.
-
LP 0145: LEO Pharma
LP-0145 is an anti-inflammatory monoclonal antibody under development for the treatment of atopic dermatitis. It is currently being evaluated in Phase II clinical trials for eczema.
Eczema Pipeline Therapeutic Assessment
Eczema Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Eczema By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Eczema Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Eczema Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Eczema therapies and key Eczema companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Eczema Current Treatment Patterns
4. Eczema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Eczema Late-Stage Products (Phase-III)
7. Eczema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Eczema Discontinued Products
13. Eczema Product Profiles
14. Eczema Key Companies
15. Eczema Key Products
16. Dormant and Discontinued Products
17. Eczema Unmet Needs
18. Eczema Future Perspectives
19. Eczema Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Eczema pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
